Search

Your search keyword '"von Essen MR"' showing total 42 results

Search Constraints

Start Over You searched for: Author "von Essen MR" Remove constraint Author: "von Essen MR"
42 results on '"von Essen MR"'

Search Results

2. Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis.

3. Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis.

4. CD11c + B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy.

5. Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine.

6. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.

7. Cladribine Effects on T and B Cells and T Cell Reactivity in Multiple Sclerosis.

8. Cerebrospinal fluid soluble CD27 is associated with CD8 + T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis.

9. Intrathecal CD8 + CD20 + T Cells in Primary Progressive Multiple Sclerosis.

10. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.

11. Peripheral helper T cells in the pathogenesis of multiple sclerosis.

12. Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis.

13. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis.

14. Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.

15. Assessment of commonly used methods to determine myelin-reactivity of T cells in multiple sclerosis.

16. IL2RA Methylation and Gene Expression in Relation to the Multiple Sclerosis-Associated Gene Variant rs2104286 and Soluble IL-2Rα in CD8 + T Cells.

17. Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis.

18. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis.

19. MAIT cell subtypes in multiple sclerosis.

20. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease.

21. Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis.

22. Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls.

23. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

24. IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis.

25. GPR15 + T cells are Th17 like, increased in smokers and associated with multiple sclerosis.

26. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.

27. B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response.

28. Inflammatory markers of CHMP2B-mediated frontotemporal dementia.

29. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.

30. Smoking reduces circulating CD26 hi CD161 hi MAIT cells in healthy individuals and patients with multiple sclerosis.

31. Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.

32. Midline 1 directs lytic granule exocytosis and cytotoxicity of mouse killer T cells.

33. Vitamin D-binding protein controls T cell responses to vitamin D.

34. Vitamin D up-regulates the vitamin D receptor by protecting it from proteasomal degradation in human CD4+ T cells.

35. The vitamin d receptor and T cell function.

36. PKC-θ exists in an oxidized inactive form in naive human T cells.

37. Mechanisms behind functional avidity maturation in T cells.

38. Activated human CD4+ T cells express transporters for both cysteine and cystine.

39. TCR down-regulation boosts T-cell-mediated cytotoxicity and protection against poxvirus infections.

40. Polymorphisms of the T cell receptor CD3delta and CD3epsilon chains affect anti-CD3 antibody binding and T cell activation.

41. Vitamin D controls T cell antigen receptor signaling and activation of human T cells.

42. TCR down-regulation controls T cell homeostasis.

Catalog

Books, media, physical & digital resources